| Nov 13 |
Lexeo Therapeutics GAAP EPS of -$0.89 misses by $0.24
|
| Nov 13 |
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
|
| Oct 30 |
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference
|
| Oct 22 |
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference
|
| Aug 12 |
Lexeo Therapeutics GAAP EPS of -$0.64
|
| Aug 12 |
Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
|
| Jul 18 |
Biotech Stock Roundup: LXRX Up on Regulatory Update, SAVA, LXEO Down on Updates
|
| Jul 16 |
Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
|
| Jul 16 |
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
|
| Jul 15 |
Update: Lexeo Shares Tumble Despite 'Positive' Data in Trials of Gene Therapy Candidate for Cardiac Disorder
|
